

Department of Health & Human Services
Centers for Medicare & Medicaid Services

Printed: 07/18/2026
Form Approved OMB
No. 0938-0391

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER: 305043	(X2) MULTIPLE CONSTRUCTION A. Building B. Wing	(X3) DATE SURVEY COMPLETED 03/04/2026
NAME OF PROVIDER OR SUPPLIER Warde Health Center		STREET ADDRESS, CITY, STATE, ZIP CODE 21 Searles Road Windham, NH 03087	
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.			
(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (Each deficiency must be preceded by full regulatory or LSC identifying information)		
F 0761 Level of Harm - Minimal harm or potential for actual harm Residents Affected - Few	Ensure drugs and biologicals used in the facility are labeled in accordance with currently accepted professional principles; and all drugs and biologicals must be stored in locked compartments, separately locked, compartments for controlled drugs. Based on observation, interview, and record review, the facility failed to ensure medications were stored safely by removing expired medications and properly labeling medications with a shortened shelf-life (such as multi-dose vials) for 1 of 1 medication carts (Resident identifiers are #3, #6, and #19.) Findings include: Observation on 3/3/26 at approximately 8:30 a.m. of the Mercy Hall Medication Cart revealed:Resident #3's Latanoprost 0.005% (percent) Ophthalmic Drops, opened and not labeled with a date of opening or expiration.Resident #6's Lantus Solostar Insulin Pen, opened and not labeled with a date of opening or expiration.Resident #19's Rhopressa 0.02% Ophthalmic Drops, opened and labeled with a date of opening of 1/12/26. Interview on 3/3/26 at approximately 8:35 a.m. with Staff A (Licensed Practical Nurse) confirmed the above findings. Review on 3/3/26 of the manufacturer's instructions for Rhopressa Ophthalmic Drops, dated 2024, revealed, . after opening the product may be kept at, . for up to 6 weeks.Review on 3/3/26 of the manufacturer's instructions for Lantus Insulin, dated 2019, revealed, The opened (in-use) Solostar device must be discarded 28 days after being opened.Review on 3/3/26 of the manufacturer's instructions for Xalatan (Latanaprost Ophthalmic Solution) 0.005%, dated 5/23, revealed, Once a bottle is opened for use, it may be stored at room temperature, ., for 6 weeks. Review on 3/3/26 of the facility policy titled, Medication Administration, General Guidelines, dated 1/21 revealed, 8. b. The nurse shall place a 'date opened' sticker on the medication if one is not provided by the dispensing pharmacy and enter the date opened. C. Certain products or package types such as multi-dose vials and ophthalmic drops have specified shortened end-of-use dating, once opened, to ensure medication purity and potency.		

Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.

LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE

TITLE

(X6) DATE